Updated View on Kidney Transplant from HCV-Infected Donors and DAAs

• Main Authors: Fabrizio Fabrizi, Roberta Cerutti, Carlo M. Alfieri, Piergiorgio Messa
• Format: Article
• Language: English
• Published: MDPI AG 2021-04-01
• Series: Pharmaceutics
• Subjects: antiviral agents; HCV viremia; hepatitis C; kidney donors; kidney transplant
• Online Access: https://www.mdpi.com/1999-4923/13/4/496

Background: The discrepancy between the number of potential available kidneys and the number of patients listed for kidney transplant continues to widen all over the world. The transplant of kidneys from hepatitis C virus (HCV)-infected donors into HCV naïve recipients has grown recently because of persistent kidney shortage and the availability of direct-acting antiviral agents. This strategy has the potential to reduce both waiting times for transplant and the risk of mortality in dialysis. Aim: We made an extensive review of the scientific literature in order to review the efficacy and safety of kidney transplant from HCV-viremic donors into HCV naïve recipients who received early antiviral therapy with direct-acting antiviral agents (DAAs). Results: Evidence has been rapidly accumulated on this topic and some reports have been published (<i>n</i> = 11 studies, <i>n</i> = 201 patients) over the last three years. Various combinations of DAAs were administered—elbasvir/grazoprevir (<i>n</i> = 38), glecaprevir/pibrentasvir (<i>n</i> = 110), and sofosbuvir-based regimens (<i>n</i> = 53). DAAs were initiated in a range between a few hours before renal transplant (RT) to a median of 76 days after RT. The sustained virological response (SVR) rate was between 97.5% and 100%. A few severe adverse events (SAEs) were noted including fibrosing cholestatic hepatitis (<i>n</i> = 3), raised serum aminotransferase levels (<i>n</i> = 11), and acute rejection (<i>n</i> = 7). It remains unclear whether the AEs were related to the transmission of HCV, the use of DAAs, or kidney transplant per se. It appears that the frequency of AEs was greater in those studies where DAAs were not given in the very early post-kidney transplant phase. Conclusions: The evidence gathered to date encourages the expansion of the kidney donor pool with the adoption of HCV-infected donor organs. We suggest that kidney transplants from HCV-viremic kidneys into HCV-uninfected recipients should be made in the context of research protocols. Many of the studies reported above were externally funded and we need research generating “real-world” evidence. The recent availability of pangenotypic combinations of DAAs, which can be given even in patients with eGFR < 30/min/1.73 m², will promote the notion that HCV-viremic donors are a significant resource for kidney transplant.